Current Report Filing (8-k)
April 18 2023 - 9:19AM
Edgar (US Regulatory)
0001722964
false
0001722964
2023-04-18
2023-04-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): April 18, 2023
Y-MABS THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-38650 |
|
47-4619612 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
230 Park Avenue
Suite 3350
New York, New York 10169
(Address of principal executive offices)
(Zip Code)
(646) 885-8505
(Registrant’s telephone number,
include area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class: |
|
Trading Symbol |
|
Name of each exchange on which
registered: |
Common Stock, $0.0001 par value |
|
YMAB |
|
NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events
On April 18, 2023, Y-mAbs Therapeutics, Inc.,
(the “Company”) issued a press release announcing that a poster presentation featuring preclinical data on naxitamab, a recombinant,
humanized anti-GD2 monoclonal antibody will be presented at the AACR Annual Meeting 2023, which takes place in Orlando, Florida from April 14-19,
2023. The poster, “Investigational novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast
cancer stem-like cells,” will be presented on April 18, 2023, from 1:30 to 5:00 pm EST. The press release further summarizes
the contents of the poster presentation. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Y-MABS THERAPEUTICS, INC. |
|
|
|
Date: April 18, 2023 |
By: |
/s/ Bo Kruse |
|
|
Bo Kruse |
|
|
Executive Vice President and Chief Financial Officer |
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024